Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation

Authors: T Stein, E Cosimo, P Smith, R Simon, K Price, L Baird, AK Bell, G Sauter, T Crook, BA Gusterson

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Reelin is a secreted signalling protein whose major function has so far been described in the developing brain, where it is involved in cell positioning of neuronal progenitor cells. Recently, the Reelin promoter has been found to be methylated in pancreatic cancer and this was associated with increased migratory ability [1], whereas in the prostate Reelin expression is associated with high-grade cancers [2]. …
Literature
1.
Sato N, Fukushima N, Chang R, et al: Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology. 2006, 130: 548-565. 10.1053/j.gastro.2005.11.008.CrossRefPubMed
2.
Perrone G, Vincenzi B, Zagami M, et al: Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol. 2007, 20: 344-351. 10.1038/modpathol.3800743.CrossRefPubMed
Metadata
Title
Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation
Authors
T Stein
E Cosimo
P Smith
R Simon
K Price
L Baird
AK Bell
G Sauter
T Crook
BA Gusterson
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1909

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

From association to cause: fine mapping of the TNRC9gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer

Poster presentation

NRG1is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene

Poster presentation

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours

Poster presentation

Understanding and exploiting changes in O-linked glycosylation in breast cancer

Poster presentation

Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models

Poster presentation

Investigation of immunoregulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits